Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers
作者： Ellen R Copson , Helen E White , Jeremy P Blaydes , David O Robinson , Peter W Johnson
关键词:
摘要: Background The MDM2 gene encodes a negative regulator of the p53 tumour suppressor protein. A single nucleotide polymorphism (SNP) in promoter (a T to G exchange at 309) has been reported produce accelerated formation individuals with inherited mutations. We have investigated effect SNP309 on clinical outcome cohort patients germline mutations BRCA1.
biomedcentral.com
springer.com
doaj.org参考文章(29)
Tak W. Mak, Anne Hakem, J. Peter McPherson, Amro Shehabeldin, Elzbieta Zablocki, Eva Migon, Gordon S. Duncan, Denis Bouchard, Andrew Wakeham, Alison Cheung, Jana Karaskova, Ildiko Sarosi, Jeremy Squire, Jamey Marth, Razqallah Hakem, Brca1 required for T cell lineage development but not TCR loci rearrangement Nature Immunology. ,vol. 1, pp. 77- 82 ,(2000) , 10.1038/76950
Kelly-Anne Phillips, Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. Journal of Clinical Oncology. ,vol. 18, ,(2000)
Susan J. Ramus, Lynda G. Bobrow, Paul D.P. Pharoah, Damon S. Finnigan, Ami Fishman, Marco Altaras, Patricia A. Harrington, Simon A. Gayther, Bruce A.J. Ponder, Lori S. Friedman, Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes, Chromosomes and Cancer. ,vol. 25, pp. 91- 96 ,(1999) , 10.1002/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5
Piri L Welcsh, Kelly N Owens, Mary-Claire King, Insights into the functions of BRCA1 and BRCA2. Trends in Genetics. ,vol. 16, pp. 69- 74 ,(2000) , 10.1016/S0168-9525(99)01930-7
Ford, D, Easton, DF, Bishop, DT, Narod, SA, Goldgar, DE and the Breast Cancer Linkage Consortium, None, Risks of cancer in BRCA1-mutation carriers The Lancet. ,vol. 343, pp. 692- 695 ,(1994) , 10.1016/S0140-6736(94)91578-4
Gareth L. Bond, Wenwei Hu, Arnold Levine, A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Research. ,vol. 65, pp. 5481- 5484 ,(2005) , 10.1158/0008-5472.CAN-05-0825
Hongbing Zhang, Kumaravel Somasundaram, Yi Peng, Hui Tian, Hongxiang Zhang, Daike Bi, Barbara L Weber, Wafik S El-Deiry, BRCA1 physically associates with p53 and stimulates its transcriptional activity Oncogene. ,vol. 16, pp. 1713- 1721 ,(1998) , 10.1038/SJ.ONC.1201932
WD Foulkes, GWH Stamp, S Afzal, N Lalani, CP McFarlane, J Trowsdale, IG Campbell, MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. British Journal of Cancer. ,vol. 72, pp. 883- 888 ,(1995) , 10.1038/BJC.1995.428
Razqallah Hakem, José Luis de la Pompa, Andrew Elia, Julia Potter, Tak W. Mak, Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nature Genetics. ,vol. 16, pp. 298- 302 ,(1997) , 10.1038/NG0797-298
Timothy R Rebbeck, Henry T Lynch, Susan L Neuhausen, Steven A Narod, Laura Van't Veer, Judy E Garber, Gareth Evans, Claudine Isaacs, Mary B Daly, Ellen Matloff, Olufunmilayo I Olopade, Barbara L Weber, None, Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations The New England Journal of Medicine. ,vol. 346, pp. 1616- 1622 ,(2002) , 10.1056/NEJMOA012158